Immune mechanisms of HIV control

Current Opinion in Immunology

Volumn 22, Issue 4, 2010, Pages 488-496

  Chakrabarti, Lisa A ^a   Simon, Viviana ^b  

^a INSTITUT PASTEUR   (France)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; HLA ANTIGEN CLASS 1; HLA C ANTIGEN; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRIPARTITE MOTIF PROTEIN 5;

ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CYTOKINE PRODUCTION; DENDRITIC CELL; EFFECTOR CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; INNATE IMMUNITY; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; NONHUMAN; REVIEW; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION;

AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE SYSTEM; KILLER CELLS, NATURAL;

EID: 77955663456     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.06.006     Document Type: Review

References (67)

1. Grabar S., Selinger-Leneman H., Abgrall S., Pialoux G., Weiss L., Costagliola D. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 2009, 23:1163-1169.
2. Saez-Cirion A., Pancino G., Sinet M., Venet A., Lambotte O. HIV controllers: how do they tame the virus?. Trends Immunol 2007, 28:532-540.
3. Deeks S.G., Walker B.D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007, 27:406-416.
4. Migueles S.A., Laborico A.C., Shupert W.L., Sabbaghian M.S., Rabin R., Hallahan C.W., Van Baarle D., Kostense S., Miedema F., McLaughlin M., et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002, 3:1061-1068.
5. Sajadi M.M., Heredia A., Le N., Constantine N.T., Redfield R.R. HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. AIDS 2007, 21:517-519.
6. Blankson J.N. Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses?. Antiviral Res 2010, 85:295-302.
7. Kumagai Y., Takeuchi O., Akira S. Pathogen recognition by innate receptors. J Infect Chemother 2008, 14:86-92.
8. Baum A., Garcia-Sastre A. Induction of type I interferon by RNA viruses: cellular receptors and their substrates. Amino Acids 2010, 38:1283-1299.
9. Meylan P.R., Guatelli J.C., Munis J.R., Richman D.D., Kornbluth R.S. Mechanisms for the inhibition of HIV replication by interferons-alpha -beta, and -gamma in primary human macrophages. Virology 1993, 193:138-148.
10. Thibault S., Fromentin R., Tardif M.R., Tremblay M.J. TLR2 and TLR4 triggering exerts contrasting effects with regard to HIV-1 infection of human dendritic cells and subsequent virus transfer to CD4+ T cells. Retrovirology 2009, 6:42.
11. Tavel J.A., Huang C.Y., Shen J., Metcalf J.A., Dewar R., Shah A., Vasudevachari M.B., Follmann D.A., Herpin B., Davey R.T., et al. Interferon-alpha produces significant decreases in HIV load. J Interferon Cytokine Res 2010 March 17.
12. Adalid-Peralta L., Godot V., Colin C., Krzysiek R., Tran T., Poignard P., Venet A., Hosmalin A., Lebon P., Rouzioux C., et al. Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection. J Leukoc Biol 2008, 83:1060-1067.
13. Vendrame D., Sourisseau M., Perrin V., Schwartz O., Mammano F. Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer. J Virol 2009, 83:10527-10537.
14. Borrow P., Bhardwaj N. Innate immune responses in primary HIV-1 infection. Curr Opin HIV AIDS 2008, 3:36-44.
15. Soumelis V., Scott I., Gheyas F., Bouhour D., Cozon G., Cotte L., Huang L., Levy J.A., Liu Y.J. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 2001, 98:906-912.
16. Schmidt B., Ashlock B.M., Foster H., Fujimura S.H., Levy J.A. HIV-infected cells are major inducers of plasmacytoid dendritic cell interferon production, maturation, and migration. Virology 2005, 343:256-266.
17. Hosmalin A., Lebon P. Type I interferon production in HIV-infected patients. J Leukoc Biol 2006, 80:984-993.
18. Ross S.R. Are viruses inhibited by APOBEC3 molecules from their host species?. PLoS Pathog 2009, 5:e1000347.
19. Neil S., Bieniasz P. Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res 2009, 29:569-580.
20. van Manen D., Rits M.A., Beugeling C., van Dort K., Schuitemaker H., Kootstra N.A. The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog 2008, 4:e18.
21. An P., Duggal P., Wang L.H., O'Brien S.J., Donfield S., Goedert J.J., Phair J., Buchbinder S., Kirk G.D., Winkler C.A. Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet 2007, 3:e19.
22. Kidd J.M., Newman T.L., Tuzun E., Kaul R., Eichler E.E. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet 2007, 3:e63.
23. An P., Johnson R., Phair J., Kirk G.D., Yu X.F., Donfield S., Buchbinder S., Goedert J.J., Winkler C.A. APOBEC3B deletion and risk of HIV-1 acquisition. J Infect Dis 2009, 200:1054-1058.
24. Refsland E.W., Stenglein M.D., Shindo K., Albin J.S., Brown W.L., Harris R.S. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 2010 March 22, [Epub ahead of print].
25. Koning F.A., Newman E.N., Kim E.Y., Kunstman K.J., Wolinsky S.M., Malim M.H. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 2009, 83:9474-9485.
26. Stoddart C.A., Keir M.E., McCune J.M. IFN-alpha-induced upregulation of CCR5 leads to expanded HIV tropism in vivo. PLoS Pathog 2010, 6:e1000766.
27. Meier A., Chang J.J., Chan E.S., Pollard R.B., Sidhu H.K., Kulkarni S., Wen T.F., Lindsay R.J., Orellana L., Mildvan D., et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009, 15:955-959.
28. Rotger M., Dang K.K., Fellay J., Heinzen E.L., Feng S., Descombes P., Shianna K.V., Ge D., Gunthard H.F., Goldstein D.B., et al. Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. PLoS Pathog 2010, 6:e1000781.
29. Pelak K., Goldstein D.B., Walley N.M., Fellay J., Ge D., Shianna K.V., Gumbs C., Gao X., Maia J.M., Cronin K.D., et al. Host determinants of HIV-1 control in African Americans. J Infect Dis 2010, 201:1141-1149.
30. Fellay J., Ge D., Shianna K.V., Colombo S., Ledergerber B., Cirulli E.T., Urban T.J., Zhang K., Gumbs C.E., Smith J.P., et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009, 5:e1000791.
31. Altfeld M., Kalife E.T., Qi Y., Streeck H., Lichterfeld M., Johnston M.N., Burgett N., Swartz M.E., Yang A., Alter G., et al. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T cell response against HIV-1. PLoS Med 2006, 3:e403.
32. Carrington M., Martin M.P., van Bergen J. KIR-HLA intercourse in HIV disease. Trends Microbiol 2008, 16:620-627.
33. Pereyra F., Addo M.M., Kaufmann D.E., Liu Y., Miura T., Rathod A., Baker B., Trocha A., Rosenberg R., Mackey E., et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008, 197:563-571.
34. Ferre A.L., Hunt P.W., Critchfield J.W., Young D.H., Morris M.M., Garcia J.C., Pollard R.B., Yee H.F., Martin J.N., Deeks S.G., et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009, 113:3978-3989.
35. Saez-Cirion A., Lacabaratz C., Lambotte O., Versmisse P., Urrutia A., Boufassa F., Barre-Sinoussi F., Delfraissy J.F., Sinet M., Pancino G., et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007, 104:6776-6781.
36. Saez-Cirion A., Sinet M., Shin S.Y., Urrutia A., Versmisse P., Lacabaratz C., Boufassa F., Avettand-Fenoel V., Rouzioux C., Delfraissy J.F., et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol 2009, 182:7828-7837.
37. Julg B., Williams K.L., Reddy S., Bishop K., Qi Y., Carrington M., Goulder P.J., Ndung'u T., Walker B.D. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J Virol 2010, 84:5540-5549.
38. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007, 13:46-53.
39. Migueles S.A., Osborne C.M., Royce C., Compton A.A., Joshi R.P., Weeks K.A., Rood J.E., Berkley A.M., Sacha J.B., Cogliano-Shutta N.A., et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008, 29:1009-1021.
40. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., Lederman M.M., Benito J.M., Goepfert P.A., Connors M., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781-4789.
41. Migueles S.A., Weeks K.A., Nou E., Berkley A.M., Rood J.E., Osborne C.M., Hallahan C.W., Cogliano-Shutta N.A., Metcalf J.A., McLaughlin M., et al. Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol 2009, 83:11876-11889.
42. Makedonas G., Hutnick N., Haney D., Amick A.C., Gardner J., Cosma G., Hersperger A.R., Dolfi D., Wherry E.J., Ferrari G., et al. Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells. PLoS Pathog 2010, 6:e1000798.
43. Emu B., Sinclair E., Hatano H., Ferre A., Shacklett B., Martin J.N., McCune J.M., Deeks S.G. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol 2008, 82:5398-5407.
44. Vojnov L., Reed J.S., Weisgrau K.L., Rakasz E.G., Loffredo J.T., Piaskowski S.M., Sacha J.B., Kolar H.L., Wilson N.A., Johnson R.P., et al. Effective simian immunodeficiency virus-specific CD8+ T cells lack an easily detectable, shared characteristic. J Virol 2010, 84:753-764.
45. Younes S.A., Yassine-Diab B., Dumont A.R., Boulassel M.R., Grossman Z., Routy J.P., Sekaly R.P. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 2003, 198:1909-1922.
46. Potter S.J., Lacabaratz C., Lambotte O., Perez-Patrigeon S., Vingert B., Sinet M., Colle J.H., Urrutia A., Scott-Algara D., Boufassa F., et al. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol 2007, 81:13904-13915.
47. van Grevenynghe J., Procopio F.A., He Z., Chomont N., Riou C., Zhang Y., Gimmig S., Boucher G., Wilkinson P., Shi Y., et al. Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat Med 2008, 14:266-274.
48. Kaufmann D.E., Kavanagh D.G., Pereyra F., Zaunders J.J., Mackey E.W., Miura T., Palmer S., Brockman M., Rathod A., Piechocka-Trocha A., et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007, 8:1246-1254.
49. Tilton J.C., Luskin M.R., Johnson A.J., Manion M., Hallahan C.W., Metcalf J.A., McLaughlin M., Davey R.T., Connors M. Changes in paracrine interleukin-2 requirement. CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load. J Virol 2007, 81:2713-2725.
50. Guihot A., Tubiana R., Breton G., Marcelin A.G., Samri A., Assoumou L., Goncalves E., Bricaire F., Costagliola D., Calvez V., et al. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. AIDS 2010, 24:614-617.
51. Sacha J.B., Giraldo-Vela J.P., Buechler M.B., Martins M.A., Maness N.J., Chung C., Wallace L.T., Leon E.J., Friedrich T.C., Wilson N.A., et al. Gag- and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc Natl Acad Sci USA 2009, 106:9791-9796.
52. Yi J.S., Cox M.A., Zajac A.J. T-cell exhaustion: characteristics, causes and conversion. Immunology 2010, 129:474-481.
53. Iannello A., Boulassel M.R., Samarani S., Debbeche O., Tremblay C., Toma E., Routy J.P., Ahmad A. Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study. J Immunol 2010, 184:114-126.
54. Vingert B., Perez-Patrigeon S., Jeannin P., Lambotte O., Boufassa F., Lemaitre F., Kwok W.W., Theodorou I., Delfraissy J.F., Theze J., et al. HIV controller CD4+ T cells respond to minimal amounts of gag antigen due to high TCR avidity. PLoS Pathog 2010, 6:e1000780.
55. Williams M.A., Ravkov E.V., Bevan M.J. Rapid culling of the CD4+ T cell repertoire in the transition from effector to memory. Immunity 2008, 28:533-545.
56. Hunt P.W., Brenchley J., Sinclair E., McCune J.M., Roland M., Page-Shafer K., Hsue P., Emu B., Krone M., Lampiris H., et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008, 197:126-133.
57. Almeida J.R., Price D.A., Papagno L., Arkoub Z.A., Sauce D., Bornstein E., Asher T.E., Samri A., Schnuriger A., Theodorou I., et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007, 204:2473-2485.
58. Almeida J.R., Sauce D., Price D.A., Papagno L., Shin S.Y., Moris A., Larsen M., Pancino G., Douek D.C., Autran B., et al. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood 2009, 113:6351-6360.
59. Alexander-Miller M.A. High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors. Immunol Res 2005, 31:13-24.
60. Lichterfeld M., Yu X.G., Mui S.K., Williams K.L., Trocha A., Brockman M.A., Allgaier R.L., Waring M.T., Koibuchi T., Johnston M.N., et al. Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J Virol 2007, 81:4199-4214.
61. Price D.A., Asher T.E., Wilson N.A., Nason M.C., Brenchley J.M., Metzler I.S., Venturi V., Gostick E., Chattopadhyay P.K., Roederer M., et al. Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. J Exp Med 2009, 206:923-936.
62. Belyakov I.M., Kuznetsov V.A., Kelsall B., Klinman D., Moniuszko M., Lemon M., Markham P.D., Pal R., Clements J.D., Lewis M.G., et al. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 2006, 107:3258-3264.
63. Neveu B., Debeaupuis E., Echasserieau K., le Moullac-Vaidye B., Gassin M., Jegou L., Decalf J., Albert M., Ferry N., Gournay J., et al. Selection of high-avidity CD8 T cells correlates with control of hepatitis C virus infection. Hepatology 2008, 48:713-722.
64. Zhu Q., Egelston C., Gagnon S., Sui Y., Belyakov I.M., Klinman D.M., Berzofsky J.A. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 2010, 120:607-616.
65. Goujard C., Chaix M.L., Lambotte O., Deveau C., Sinet M., Guergnon J., Courgnaud V., Rouzioux C., Delfraissy J.F., Venet A., et al. Spontaneous control of viral replication during primary HIV infection: when is " HIV controller" status established?. Clin Infect Dis 2009, 49:982-986.
66. Okulicz J.F., Marconi V.C., Landrum M.L., Wegner S., Weintrob A., Ganesan A., Hale B., Crum-Cianflone N., Delmar J., Barthel V., et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 2009, 200:1714-1723.
67. Lambotte O., Ferrari G., Moog C., Yates N.L., Liao H.X., Parks R.J., Hicks C.B., Owzar K., Tomaras G.D., Montefiori D.C., et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009, 23:897-906.